IDeAS Probiotic Pilot (IDeAS)
Investigating Staphylococcus Aureus Colonization Dynamics in the Context of Bacillus Probiotic
Infections caused by Staphylococcus aureus pose a major public health threat, and existing prevention methods are burdensome to patients and provide only limited benefit. In this collaborative study, participants will trial a probiotic intervention and share their perspectives regarding study design and feasibility. The goal of this study is to characterize colonization kinetics of S. aureus and B. subtilis in the nares, skin, and stool before, during, and after administration of a nutritional supplement probiotic blend. We will establish the S. aureus intestinal colonization kinetics over a 3-month Natural History Phase, followed by a 1-month administration of the probiotic (Intervention Phase), and a 3-month Post-Intervention Observational Phase. Samples from the nares, skin, and stool will be collected at each of the 10 study visits to detect S. aureus and B. subtilis. We will also conduct interviews to assess acceptability, appropriateness, and feasibility of the probiotic and study regimen.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The ongoing epidemic of Staphylococcus aureus skin and soft tissue infections in healthy individuals is a significant public health burden. S. aureus colonization (having the germ living in or on the body without symptoms) poses risk for developing symptomatic S. aureus infections. Thus, topical antimicrobials and antiseptics are often used to eliminate or reduce the burden of S. aureus from the nose and skin (known as decolonization). While current decolonization practices with topical antimicrobials effectively eliminate S. aureus carriage and prevent recurrent infections in the immediate period, their effectiveness wanes over time. While the nose has traditionally been considered the primary reservoir of S. aureus carriage, the intestine is also an important, yet under-appreciated, reservoir of S. aureus. Intestinal colonization can lead to persistent S. aureus colonization at other body sites despite topical antimicrobial decolonization.
Probiotics can promote a healthy gut microbiome by increasing the presence of beneficial bacteria and reducing the presence of pathogens, thereby improving digestive health and enhancing immune function. Bacillus subtilis is a benign microorganism that has been shown to inhibit S. aureus from colonizing the intestine. In a trial conducted in rural Thailand, daily oral administration of B. subtilis MB40 significantly reduced S. aureus in stool and nasal samples, without adverse effects. Bacillus coagulans has been demonstrated to decrease gastrointestinal symptoms, without adverse effects. B. subtilis and B. coagulans are both included as supplements in foods and available in pill form. In this investigation, we will study a probiotic blend of B. subtilis and B. coagulans, which is commercially available as a nutritional supplement, Ameo LifeTM Digest Probiotic. The goals of this study are to 1) establish the longitudinal colonization kinetics of S. aureus and B. subtilis before, during, and after probiotic administration; 2) assess the tolerability and delivery fidelity of the probiotic administration; and 3) engage participant perspectives to optimize study procedures and develop an intervention that is acceptable, appropriate, feasible, and likely to be adopted in real-world settings.
In this study, 20 healthy adults who are at risk for S. aureus infection who are colonized with S. aureus will be enrolled. S. aureus-colonized participants will be followed during a 3-month Natural History Phase, followed by a 1-month administration of the probiotic, and finally, a 3-month Post-Intervention Observational Phase. Stool, nasal, and skin samples will be collected 10 times over 7 months to quantify S. aureus and B. subtilis longitudinally. Participant acceptability and appropriateness will be assessed through brief, semi-structured interviews at the end of the probiotic administration and the conclusion of the Post-Intervention Observational Phase.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Stephanie Fritz, MD, MSCI
- Phone Number: (314) 454-4114
- Email: Fritz.s@wustl.edu
Study Contact Backup
- Name: Mary Boyle, RN, MSN
- Phone Number: 3(14) 286-1207
- Email: mboyle@wustl.edu
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Participants meeting eligibility criteria who provide written informed consent. Participants will be recruited from a pre-existing participant pool developed through prior studies conducted by our research team. Participants will be from St. Louis, Missouri and surrounding areas.
Description
Inclusion Criteria
- Colonized with S. aureus in anterior nares, inguinal folds, or stool
- Age ≥ 18 years
- Able to complete the informed consent process
- Willing and able to complete the study protocol, study-related activities, and visits
Exclusion Criteria
- Pregnant or planning to become pregnant in the next 9 months
- Breastfeeding
- Abnormalities of the gastrointestinal tract (e.g., inflammatory bowel disease, ulcers, celiac diseases, etc.)
- Immunodeficiency
- Use of any antibiotics or probiotics outside of the study within 90 days of study screening
- Any contraindication to taking probiotics
- No permanent home, or living in a group home/ long term care facility
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Characterize S. aureus in the stool from the pre-intervention sampling to the Week 4 sampling (completion of the Intervention Phase)
Time Frame: Start of the pre-intervention phase and end of the intervention phase
|
Compare change in S. aureus log10 S. aureus CFU/g count in stool from the pre-intervention sampling to the week-4 (end-of-dosing) sampling. |
Start of the pre-intervention phase and end of the intervention phase
|
|
Evaluate the implementation outcomes of acceptability, appropriateness, and feasibility of the study procedures from the participant's perspective.
Time Frame: End of the intervention phase and end of the post-intervention phase
|
Create a participant-informed account of what makes the regimen acceptable and appropriate, benchmarked feasibility data against pre-specified go/no-go thresholds, and a prioritized set of protocol refinements. Comparing facilitators and barriers at the end-of-intervention visit versus the end-of-follow-up visit will indicate whether acceptability changes over time, and benchmarks falling below the thresholds will pinpoint where recruitment, retention, or scheduling procedures require modification. |
End of the intervention phase and end of the post-intervention phase
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
S. aureus nares pre-intervention to week-4 (end-of-dosing) sampling.
Time Frame: Pre-intervention to week-4 sampling
|
Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to week-4 (end-of-dosing) sampling. |
Pre-intervention to week-4 sampling
|
|
S. aureus nares pre-intervention to week-6 sampling.
Time Frame: Pre-intervention to week-6 sampling
|
Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to week-6 sampling. |
Pre-intervention to week-6 sampling
|
|
S. aureus nares pre-intervention to month 2 sampling.
Time Frame: Pre-intervention sampling to month 2 sampling.
|
Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 2 sampling. |
Pre-intervention sampling to month 2 sampling.
|
|
S. aureus nares pre-intervention to month 3 sampling.
Time Frame: Pre-intervention sampling to month 3 sampling.
|
Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 3 sampling. |
Pre-intervention sampling to month 3 sampling.
|
|
S. aureus nares pre-intervention to month 4 sampling.
Time Frame: Pre-intervention to month 4 sampling.
|
Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 4 sampling. |
Pre-intervention to month 4 sampling.
|
|
S. aureus inguinal fold pre-intervention to week-4 (end-of-dosing) sampling.
Time Frame: Pre-intervention to week-4 sampling
|
Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to week-4 (end-of-dosing) sampling. |
Pre-intervention to week-4 sampling
|
|
S. aureus inguinal fold pre-intervention to week-6 sampling.
Time Frame: Pre-intervention to week-6 sampling
|
Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to week-6 sampling. |
Pre-intervention to week-6 sampling
|
|
S. aureus inguinal fold pre-intervention to month 2 sampling.
Time Frame: Pre-intervention sampling to month 2 sampling.
|
Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 2 sampling. |
Pre-intervention sampling to month 2 sampling.
|
|
S. aureus inguinal fold pre-intervention to month 3 sampling.
Time Frame: Pre-intervention sampling to month 3 sampling.
|
Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 3 sampling. |
Pre-intervention sampling to month 3 sampling.
|
|
S. aureus inguinal fold pre-intervention to month 4 sampling.
Time Frame: Pre-intervention sampling to month 4 sampling.
|
Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 4 sampling. |
Pre-intervention sampling to month 4 sampling.
|
|
Bacillus stool pre-intervention
Time Frame: Pre-intervention sampling
|
log10 B. subtilis CFU count at pre-intervention sampling |
Pre-intervention sampling
|
|
Bacillus stool week-2 sampling
Time Frame: Week-2 sampling
|
log10 B. subtilis CFU count at week-2 sampling |
Week-2 sampling
|
|
Bacillus stool week-4 sampling
Time Frame: Week-4 sampling
|
log10 B. subtilis CFU count at week-4 sampling |
Week-4 sampling
|
|
Bacillus stool week-6 sampling
Time Frame: Week-6 sampling
|
log10 B. subtilis CFU count at week-6 sampling |
Week-6 sampling
|
|
Bacillus stool month 2 sampling
Time Frame: Month 2 sampling
|
log10 B. subtilis CFU count at month 2 sampling |
Month 2 sampling
|
|
Bacillus stool month 3 sampling
Time Frame: Month 3 sampling
|
log10 B. subtilis CFU count at month 3 sampling |
Month 3 sampling
|
|
Bacillus stool month 4 sampling
Time Frame: Month 4 sampling
|
log10 B. subtilis CFU count at month 4 sampling |
Month 4 sampling
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Stephanie A Fritz, MD, MSCI, Washington University School of Medicine
Publications and helpful links
General Publications
- Piewngam P, Zheng Y, Nguyen TH, Dickey SW, Joo HS, Villaruz AE, Glose KA, Fisher EL, Hunt RL, Li B, Chiou J, Pharkjaksu S, Khongthong S, Cheung GYC, Kiratisin P, Otto M. Pathogen elimination by probiotic Bacillus via signalling interference. Nature. 2018 Oct;562(7728):532-537. doi: 10.1038/s41586-018-0616-y. Epub 2018 Oct 10.
- Piewngam P, Khongthong S, Roekngam N, Theapparat Y, Sunpaweravong S, Faroongsarng D, Otto M. Probiotic for pathogen-specific Staphylococcus aureus decolonisation in Thailand: a phase 2, double-blind, randomised, placebo-controlled trial. Lancet Microbe. 2023 Feb;4(2):e75-e83. doi: 10.1016/S2666-5247(22)00322-6. Epub 2023 Jan 13.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 202609172
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.